Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 4,825 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Nina S. Kjellson sold 4,825 shares of the company's stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $16.26, for a total value of $78,454.50. Following the sale, the director now owns 3,702,595 shares of the company's stock, valued at approximately $60,204,194.70. This represents a 0.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tyra Biosciences Trading Down 2.4 %

NASDAQ:TYRA traded down $0.38 during trading hours on Monday, hitting $15.50. 170,982 shares of the company were exchanged, compared to its average volume of 264,918. The stock has a market capitalization of $784.35 million, a price-to-earnings ratio of -9.63 and a beta of 1.04. Tyra Biosciences, Inc. has a one year low of $12.48 and a one year high of $29.60. The company has a fifty day simple moving average of $15.38 and a 200 day simple moving average of $19.12.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.01). Equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on TYRA. UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective for the company. Bank of America raised Tyra Biosciences from a "neutral" rating to a "buy" rating and raised their price objective for the company from $22.00 to $31.00 in a report on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Monday, January 13th. Finally, Wedbush reissued an "outperform" rating and set a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $30.50.

Institutional Investors Weigh In On Tyra Biosciences

Large investors have recently modified their holdings of the company. FMR LLC boosted its position in Tyra Biosciences by 0.8% during the third quarter. FMR LLC now owns 3,372,850 shares of the company's stock valued at $79,296,000 after acquiring an additional 26,187 shares during the last quarter. Janus Henderson Group PLC acquired a new position in shares of Tyra Biosciences in the 3rd quarter valued at about $24,994,000. Perceptive Advisors LLC boosted its position in shares of Tyra Biosciences by 50.5% during the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company's stock valued at $16,108,000 after purchasing an additional 338,208 shares in the last quarter. State Street Corp grew its stake in Tyra Biosciences by 4.4% during the third quarter. State Street Corp now owns 384,732 shares of the company's stock worth $9,045,000 after purchasing an additional 16,248 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after buying an additional 3,896 shares during the period. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.